📇 Rhumatologue · LE MANS · (72) · Salarié

MME Laetitia ANDOLFI-BEAUVAIS

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Praticien-chercheur
13 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
77.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LE MANS (72)SalariéRPPS 10004088745

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

EHPAD LE MONTHEARD
2 ALL JEAN LURCAT, 72000 LE MANS
☎ 0243402600Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2020

📚 88 citations🎯 RCR 6.07Top 6% NIH🔓 Open Access📄 PDF gratuit ↗

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts

Theranostics · 2020

📚 50 citations🎯 RCR 2.28Top 23% NIH🔓 Open Access📄 PDF gratuit ↗

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis

Lupus · 2008

📚 37 citations🎯 RCR 1.46🩺 Clinique

Lire l'abstract Crossref ↓

Mycophenolate mofetil (MMF) with prednisolone has been associated with high remission rates when used as induction treatment for lupus nephritis. This prospective, multicentre, cohort study investigates the efficacy and safety of this regimen over 24 weeks in 213 Chinese patients with active lupus nephritis (Classes III, IV, V or combination). Baseline activity index (AI) was 6.91 ± 3.33 and chronicity index (CI) was 1.9 ± 1.2. The remission rate was 82.6% at 24 weeks (complete remission, 34.3%; partial remission, 48.4%). There were significant ( P < 0.01) improvements in kidney function shown by reductions in proteinuria, serum albumin, serum creatinine and creatinine clearance, as well as in systemic lupus erythematosus disease activity index (SLEDAI) scores. Independent risk factors influencing remission were pathological classification (including Class V and III or Class V and IV nephritis) and elevated serum creatinine at baseline (OR 2.967, 95% CI: 1.479–6.332, P = 0.001 and OR 1.007, 95% CI: 1.002–1.011, P = 0.001, respectively). Patients with concomitant membranous features on biopsy had a lower remission rate than those with Class III and IV nephritis (66.7% vs 87.3%, P = 0.002). Renal biopsy was repeated in 25 patients following treatment. There was a transition to less severe pathological morphologies in majority of subjects. Infections were monitored throughout treatment: eight patients (3.8%) experienced bacterial infections, whereas herpes zoster occurred in seven patients. Nine patients (4.2%) suffered from gastrointestinal upset, which resolved without discontinuation of MMF. One patient became leucopenic, whereas another died from active disease unrelated to kidney symptoms. MMF combined with prednisolone is an effective and well-tolerated induction treatment for patients with active lupus nephritis and for controlling SLE systemic activity.

Cookies & analyse de trafic

MME Laetitia ANDOLFI-BEAUVAIS

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (13) — classées par pathologie

Transversal4

Pédiatrie3

Case report / série2

Recommandations2

Corticothérapie1

Génétique1

Revue / méta-analyse1

Revue générale1

Partager cette fiche